BioLife Solutions (BLFS) Set to Announce Quarterly Earnings on Tuesday

BioLife Solutions (NASDAQ:BLFS) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

BioLife Solutions (NASDAQ:BLFS) last announced its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. The business had revenue of $28.33 million during the quarter, compared to analyst estimates of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. On average, analysts expect BioLife Solutions to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

BioLife Solutions Stock Performance

BLFS stock opened at $26.13 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81. BioLife Solutions has a 1 year low of $9.92 and a 1 year high of $27.36. The company has a market cap of $1.21 billion, a P/E ratio of -15.46 and a beta of 1.88. The stock’s fifty day moving average price is $24.07 and its 200-day moving average price is $22.55.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Northland Securities upped their price target on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday, August 9th. HC Wainwright began coverage on shares of BioLife Solutions in a research report on Monday, September 30th. They set a “buy” rating and a $29.00 price objective on the stock. Craig Hallum upped their target price on shares of BioLife Solutions from $23.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Finally, TD Cowen increased their price target on BioLife Solutions from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, July 17th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and an average price target of $26.67.

Insiders Place Their Bets

In other news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $23.90, for a total transaction of $239,000.00. Following the completion of the transaction, the executive vice president now directly owns 317,716 shares in the company, valued at approximately $7,593,412.40. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Aby J. Mathew sold 10,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $23.90, for a total value of $239,000.00. Following the completion of the transaction, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,593,412.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $25.12, for a total value of $77,118.40. Following the completion of the transaction, the executive now owns 114,773 shares of the company’s stock, valued at approximately $2,883,097.76. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 27,044 shares of company stock valued at $645,105 in the last quarter. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.